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Nuclear Factor κB Inhibitors Alleviate 
and the Proteasome Inhibitor PS-341 
Exacerbates Radiation Toxicity 
in Zebrafish Embryos
Abstract
Inflammatory changes are a major component of the normal tissue response to ionizing radiation, 
and increased nuclear factor κB (NF-κB) activity is an important mediator of inflammatory responses. 
Here, we used zebrafish embryos to assess the capacity of two different classes of pharmacologic agents 
known to target NF-κB to modify radiation toxicity in the vertebrate organism. These were proteasome 
inhibitors, including lactacystin, MG132, and PS-341 (Bortezomib/VELCADE), and direct inhibitors of 
NF-κB activity, including ethyl pyruvate (EP) and the synthetic triterpenoid CDDO-TFEA (RTA401), 
among others. The proteasome inhibitors either did not significantly affect radiation sensitivity of 
zebrafish embryos (MG132, lactacystin) or rendered zebrafish embryos more sensitive to the lethal 
effects of ionizing radiation (PS-341). Radiosensitization by PS-341 was reduced in fish with impaired 
p53 expression or function but not associated with enhanced expression of select p53 target genes. In 
contrast, the direct NF-κB inhibitors EP and CDDO-TFEA significantly improved overall survival of 
lethally irradiated zebrafish embryos. In addition, direct NF-κB inhibition reduced radiation-induced 
apoptosis in the central nervous system, abrogated aberrations in body axis development, restored 
metabolization and secretion of a reporter lipid through the gastrointestinal system, and improved renal
clearance compromised by radiation. In contrast to amifostine, EP and CDDO-TFEA not only protected 
against but also mitigated radiation toxicity when given 1 to 2 hours postexposure. Finally, four 
additional IκB kinase inhibitors with distinct mechanisms of action similarly improved overall survival of 
lethally irradiated zebrafish embryos. In conclusion, inhibitors of canonical pathways to NF-κB activation 
may be useful in alleviating radiation toxicity in patients. [Mol Cancer Ther 2009;8(9):2625-34]
Introduction
Normal tissue damage limits the dose of ionizing radiation that can be safely administered to 
treat neoplastic disease. A well-known example of this problem is inflammation of the oral 
mucosa and of the lining of the gastrointestinal tract in tumor patients receiving chemotherapy or 
radiation.1 Depending on the area of the body treated with radiation, other organ sites including 
the lungs and the pericardium also manifest radiation-induced inflammation. A pervasive 
feature of ionizing radiation–associated inflammation is the increased presence of proinflammatory 
cytokines including tumor necrosis factor-α (TNF-α) and interleukin-6, both locally and in 
the circulation.2 In contrast to intracellular regulators of the DNA damage response, these 
and other inflammatory mediators act in a paracrine fashion affecting diverse cell types in the 
tissue microenvironment or even at a distance.3 This circumstance highlights the necessity to 
use animal models to investigate the relative contribution of inflammatory changes to the 
overall response to radiation-induced cell and tissue injury in a multicellular organism. 
In recognition of this need, we recently 
established zebrafish embryos as a facile 
vertebrate in vivo system to monitor the effects 
of radiation protectors on normal tissues
during development.4
The nuclear factor κB (NF-κB) family of 
transcription factors represents a diverse and 
shared signaling mechanism activated during 
cell stress responses.5 In addition, deregulated 
NF-κB signaling has been implicated in the 
malignant phenotype and treatment resistance 
of select tumor forms.6-10 The canonical pathway 
to NF-κB activation leads to IκB kinase 
β (IKKβ)-dependent phosphorylation and 
subsequent proteasomal degradation of the
NF-κB inhibitor IκB, increased nuclear presence 
of NF-κB dimers, and enhanced NF-κB–
dependent transcriptional activity.5 
Whole-body radioprotection through anti-
inflammatory agents has very recently been 
shown in animal models. Specifically, certain 
triterpenoids (CDDO and derivatives thereof) 
have been shown to selectively protect normal 
mouse tissues against the deleterious effects of 
ionizing radiation.11 Furthermore, ethyl pyruvate 
(EP), a derivative of the end product of 
glycolysis, similarly protects normal cells against 
the deleterious effects of radiation both in vitro 
and in mice.12 Among other molecular targets, 
both drugs inhibit activation of NF-κB. 
EP inhibits NF-κB signaling through direct 
molecular interaction with a reactive cysteine of 
the p65 subunit of NF-κB13 whereas CDDO-
TFEA binds to a reactive cysteine (Cys179) of 
IKKα, thus inhibiting its kinase activity.14 
However, these drugs also target other signaling 
molecules and pathways of potential relevance 
to the radiation response, including signal 
transducers and activators of transcription 
3 and Jaks.15, 16 In addition to these agents 
proteasome inhibitors have been shown to
inhibit NF-κB–dependent transcription, and 
one of these (PS-341; Bortezomib; VELCADE) 
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has been Food and Drug Administration–approved for clinical use 
in patients afflicted with multiple myeloma (for review see refs.17, 18). 
It is presently unknown whether and how proteasome inhibitors affect 
whole-body radiation sensitivity.
Collectively, these results raised the question whether inhibition of 
NF-κB activity by different pharmacologic agents contributes to the 
protection of normal cells and tissues against damage induced by ionizing 
radiation. Here, we addressed this issue using zebrafish embryos as an 
in vivo model system. We observed that the NF-κB inhibitors EP and 
CDDO-TFEA afforded protection to zebrafish embryos against the 
lethal effects of radiation in the pre-exposure and postexposure settings, 
i.e., when administered hours after radiation exposure. Radiation 
protection extended to multiple organ sites including the gastrointestinal 
system and, importantly, was also observed when using additional IKK 
inhibitors with different modes of action. In contrast, several proteasome 
inhibitors, including PS-341, did not protect against, but rather moderately 
exacerbated radiation-associated normal tissue toxicity in zebrafish 
embryos. These results predict a favorable therapeutic index for the use 
of inhibitors of canonical pathways to NF-κB activation in combination 
with radiation therapy.
Materials and Methods
Embryo Harvesting and Maintenance
Zebrafish were mated in embryo collection tanks. Viable embryos were 
washed and sorted (25 embryos per 60-mm dish) at the one- to two-
cell developmental stage, and maintained under normoxic conditions at 
28.5°C to enable normal development. Embryo medium was changed at 
24, 72, and 120 h postfertilization (hpf). All procedures using live zebrafish 
were approved by the Institutional Animal Care and Use Committee at 
Thomas Jefferson University. In select experiments, embryos (24 hpf) 
were dechorionated by placement in embryo medium supplemented 
with 50 μg/mL pronase (Sigma) for approximately 10 min at room 
temperature, then gently agitated with a plastic pipette until the embryos 
were liberated from the disrupted chorions. After dechorionation, the 
embryos were rinsed thoroughly with embryo medium, and placed 
in fresh embryo medium.
Radiation Exposure and Drug Treatments
Pharmacological agents [EP was kindly provided by CDDO-TFEA 
was from Reata Pharmaceuticals; IKK inhibitor 2 (Weldelolactone), 
IKK inhibitor 3 (BMS-345541), IKK-2 inhibitor 4, and IKK-2 inhibitor 
5 (IMD-0354) were from Calbiochem; MG132 was from Sigma; PS-341 
was from Millennium Pharmaceuticals; and lactacystin was from 
Calbiochem) were dissolved in embryo medium containing <0.1% DMSO. 
Embryo medium was used as a vehicle control in all experiments. Unless 
stated otherwise embryos were exposed to ionizing radiation ranging in 
dose from 0 to 20 Gy at 24 hpf using an X-ray machine (Gulmay Medical) 
or a 137Cs radiation source. Toxicity analyses for EP (<10 mmol/L), 
CDDO-TFEA (<10 μmol/L), PS-341 (<10 μmol/L), MG132 (<50 
μmol/L), or lactacystin (<10 μmol/L) were conducted by monitoring 
survival and development of zebrafish embryos for 7 d in the absence of 
radiation. To determine modulation of radiation-induced toxicity, EP 
(1 mmol/L) or CDDO-TFEA (1 μmol/L) was added to embryos either 
1 h before or up to 3 h after radiation exposure at 24 hpf. The proteasome 
inhibitors were added to zebrafish embryos 1 h prior to ionizing radiation. 
After irradiation, zebrafish embryos were maintained at 28.5°C for up 
to 7 d postfertilization to monitor effects of treatments on survival,
morphology, and organ-specific toxicity.
Analysis of Treatment Effects on Zebrafish Survival and 
Gross Morphology
Dechorionated embryos at 72 hpf were anesthetized with a 1:100 dilution of 
4 mg/mL tricaine methanesulfonate (Sigma) and immobilized by placing 
them on 3% methylcellulose on a glass depression slide. Morphology 
was assessed visually using a light transmission microscope (Olympus 
BX51, Olympus) at 40 to 100× magnification, and representative images 
recorded using a QIMAGING camera and QIMAGING Advanced 
software (QIMAGING Diagnostic Instruments). Similarly, survival of 
embryos was assessed visually at 24-h intervals up to 7 days by light 
microscopy. The criterion for embryonic survival was the presence of 
cardiac contractions.
Apoptosis Assay
Zebrafish embryos were incubated for 1 h in embryo medium containing 
modifiers of the radiation response and exposed to 20 Gy at 24 hpf. Six 
hours after radiation exposure, embryos were stained for 15 min using 5 
μg/mL of acridine orange dye (Sigma) and rinsed five times with embryo 
medium as described previously.19 Zebrafish embryos were imaged with 
QIMAGING camera and iVision software; the images were analyzed 
using ImageJ software.
Detection of ROS
Reactive oxygen species (ROS) levels were measured in dechorionated 
zebrafish embryos in 96-well plates. Embryos (1 embryo/well) were 
treated with either vehicle (embryo medium) or EP (1 mmol/L) or 
CDDO-TFEA (1 μmol/L) in the presence of 5-(and-6)-chloromethyl-
2´,7´-dihydrodichlorofluorescein diacetate (CM-H2DCFA; 500 ng/mL; 
Molecular Probes) followed by radiation exposure at 24 hpf. The
average fluorescence emission at 530 nm following excitation at 490 
nm was detected immediately and 2 h after ionizing radiation exposure 
using a microplate fluorescent reader (BIO-TEK FL 600, BIO-TEK 
Instruments Inc.). To account for radiation-induced ROS in the embryo 
medium results were corrected by subtraction of values obtained in wells 
not containing fish in the presence and absence of pharmacologic agents.
Renal Function Assay
Time-dependent clearance of tetramethylrhodamine-labeled 10-kDa 
dextran (Molecular Probes) was determined as described previously with 
minor modifications.20 Briefly, zebrafish embryos at 24 hpf were exposed to 
ionizing radiation and maintained in embryo medium. At 72 hpf 
embryos were anesthetized using a 1:100 dilution of 4 mg/mL tricaine 
methanesulfonate (Sigma) and dorsally positioned on 3% methylcellulose 
gel. Tetramethylrhodamine-labeled 10-kDa dextran was injected into 
the cardiac venous sinus; embryos were kept at 28.5°C, and imaged at 1 
and 24 h following microinjection. The average fluorescence emission at 
590 nm following excitation at 570 nm was detected at the center of the 
cardiac area, and the relative intensity was measured using a Leica micro-
scope (Leica Mikroskopie & Systeme GmbH). Images were transformed 
into grayscale and evaluated with NIH ImageJ software as described.20
Morphologic Analysis of the Gastrointestinal System
The functional and morphologic integrity of the developing gastro-
intestinal system was assessed in zebrafish embryos using PED6, a 
fluorescent reporter of phospholipase A2 (PLA2) activity. PED6 is a fluoro-
genic substrate for PLA2, which contains a BODIPY FL dye-labeled acyl 
chain and a dinitrophenyl quencher group.21 The cleavage of the dye-
labeled acyl chain by PLA2 within cells lining the intestine unquenches the 
dye and leads to detectable fluorescence in the lumen of the developing 
gastrointestinal tract. PED6 was added to zebrafish embryos at 5 dpf 
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followed by imaging the fish at 6 dpf with the average fluorescence
emission at 540 nm excitation at 505 nm. Images were taken at 6 dpf 
using a Leica microscope and analyzed using the ImageJ software.
Histopathology and Evaluation of Tissue Morphology
Zebrafish embryos were evaluated histopathologically for morphologic 
alterations induced by radiation exposure and potential radioprotective 
effects of EP and CDDO-TFEA with special emphasis on the gastroin-
testinal morphology. Briefly, embryos at 24 hpf were exposed to 0 or 12 
Gy in the presence or absence of either CDDO-TFEA or EP administered 
1 h prior to ionizing radiation. Embryos were sacrificed, fixed by immer-
sion in 4 % paraformaldehyde for 24 h, and then rinsed and placed in 10× 
PBS for another 24 h. Sections were embedded in paraffin, and coronal, 
transverse, and sagittal whole-body sections (4 μm thickness) were gen-
erated. All sections were stained with H&E, mounted on glass slides, and 
examined by light microscope; representative images were taken using a 
QIMAGING camera and iVision software.
NF-κB Reporter Assay
NF-κB reporter assay was done as described by us previously 22 with 
minor modifications. HeLa cells were seeded at 7.5 × 104/mL in DMEM 
supplemented with 10% fetal bovine serum. The cells were cotransfected 
with the pSEAP2-NF-κB vector (BDBioSciences) encoding a secreted 
form of human placental alkaline phosphatase driven by a NF-κB–
responsive promoter and a β-galactosidase expression vector for control 
purposes. Forty-eight hours posttransfection, different NF-κB inhibitors 
(0.5 μmol/L velcade, 5 μmol/L MG-132, 1 mmol/L EP, 1 μmol/L CDDO) 
were added to the cells in serum-free media for 24 h. NF-κB–dependent 
transcription in the absence and presence of recombinant TNF-α (10 ng/
mL; R&DSystems) was determined 72 h posttransfection using the Great 
EscAPe SEAP Reporter System 3, which is based on detection of secreted 
alkaline phosphatase in cell supernatants normalized to β-galactosidase 
activity using the luminescent β-gal detection kit (BDBiosciences).
Reverse Transcription PCR Analysis
Zebrafish total RNA was isolated from 100 embryos per experimental 
condition at 30 hpf (6 h post radiation) using the RNeasy mini kit 
(QIAGEN Sciences) and stored at −80°C. For reverse transcription, total 
RNA was annealed with Oligo(dT) primer (Roche) at 70°C for 5 min 
followed by the incubation at 42°C for 1 h. Reverse transcription reaction 
products were boiled for 2 min followed by incubation on ice for 2 min 
before use. Primer sequences used for amplification of bax, mdm2, p21/
waf-1, and β-actin zebrafish sequences are provided in Supplementary 
Table S1. PCR reaction conditions were 94°C, 60°C, 72°C for 30 s, 30 s, 1 
min, respectively, and 35 cycles with 7 min extension time after the last cycle. 
Thermo Fisher Scientific Taq-polymerase was used in 50 μL PCR reaction 
mix containing 1 μL reverse transcription reaction. PCR reactions were 
analyzed by 1.5% agarose gel electrophoresis.
Statistical Analysis
All experiments were done at least three times with at least 75 embryos
total per experimental group. To determine statistically significant 
differences between groups χ2 tests were done.
Results
Proteasome Inhibitors Radiosensitize Zebrafish Embryos
The proteasome inhibitor PS-341 (Bortezomib/VELCADE) is presently 
the only Food and Drug Administration–approved drug with well-
characterized inhibitory effects on NF-κB activity.18 PS-341 is a small, 
cell-permeable molecule inhibiting proteasome activity in a reversible 
manner. In addition to reducing the activation state of NF-κB by inhibiting 
proteasomal degradation of IκB, PS-341 affects many other pathways 
and targets, leading to high expression levels of several proapoptotic 
proteins in certain experimental conditions.23 In vitro, PS-341 has been 
found to enhance antitumor cell effects of select chemotherapeutic 
agents6,24, tumor cell targeting antibodies25, and ionizing radiation26. 
Yet, little is known about the combined effects of PS-341 and ionizing 
radiation on normal cells and tissues of vertebrate organisms. To address 
this issue we used PS-341 in zebrafish embryos exposed to high doses of 
ionizing radiation as described by us previously.4, 27, 28 We first established 
that treatment of zebrafish with PS-341 alone (dose range, 0–10 μmol/L) 
was nontoxic as assessed by embryo survival and gross morphology during
the first 7 days after fertilization (Supplementary Fig. S1). In contrast, PS-341 
(1 μmol/L) markedly sensitized zebrafish embryos to the lethal effects of 
ionizing radiation when administered 1 hour prior to radiation (Fig. 1A). 
In these experiments zebrafish embryos were exposed at 24 hpf to 20 Gy, 
previously determined to kill 50% of irradiated zebrafish embryos by day 
7 of development.27 In HeLa cells, at the same concentration (1 μmol/L) 
PS-341 abrogated the TNF-α–induced NF-κB activity, whereas it did not 
significantly affect the basal activity (Supplementary Fig. 2A and B).
To ascertain whether radiation sensitization by PS-341 could be replicated 
using other inhibitors of the proteasome we next tested the effects of 
MG132, a nonboronated small molecule inhibitor of the 26S proteasome,29 
on zebrafish survival in the presence and absence of ionizing 
radiation. Similar to PS-341, MG132 was remarkably nontoxic when 
applied as a single agent to zebrafish embryos (dose range, 0–50 μmol/L) yet 
efficiently inhibited TNF-α–induced but not the baseline NF-κB activity 
in HeLa cells when used at 5 μmol/L (Supplementary Fig. 2A and B). 
At this concentration, however, MG132 marginally sensitized zebrafish 
embryos to the lethal effects of 20 Gy ionizing radiation albeit to a lesser 
degree than PS-341 (Fig. 1B). An irreversible proteasome inhibitor 
(lactacystin) at a nontoxic concentration (5 μmol/L) also slightly radio-
sensitized zebrafish embryos in a manner similar to MG132 (Fig. 1C).
These results show that several proteasome inhibitors do not protect normal 
cells and tissues in the developing fish larvae against the deleterious 
effects of radiation. As p53 is a major target of proteasomal degradation 
and enhances ionizing radiation–associated tissue damage in mice30–32 
and zebrafish33, 34 we asked whether the deleterious effects of proteasome 
inhibitors could be linked to p53 stabilization and subsequent induction 
of target genes. Consistent with our earlier observations, ablating 
p53 expression by antisense morpholino oligodeoxynucleotide35 or p53 
function by PFT-α (1 μmol/L) given to zebrafish embryos at 24 hpf34 
markedly improved zebrafish survival after radiation either alone or in 
combination with PS-341 (not shown). However, reverse transcription-
PCR analysis did not reveal increased steady-state mRNA levels of 
the p53 targets p21/WAF1, bax, or the zebrafish ortholog of mdm2 in 
PS-341–treated embryos whereas ionizing radiation led, as expected, to 
elevated transcript levels for these genes (Supplementary Fig. S3). Thus, 
the molecular target(s) responsible for radiosensitization by PS-341 and 
their relationship, if any, to the p53 response remain to be identified.
Radiation Protection of Zebrafish Embryos by the NF-κBp65 
Inhibitor Ethyl Pyruvate
In consideration of the fact that proteasome inhibitors affect multiple 
intracellular pathways in addition to NF-κB and to pinpoint the functional 
contribution of NF-κB to the radiation response of zebrafish embryos, we 
tested the effects of a series of pharmacologic inhibitors of NF-κB activity 
with different mechanisms of action on the radiation response of zebrafish 
embryos. Reducing NF-κB activity by expression of upstream regulator 
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Figure 1. Effects of the proteasome inhibitors PS-341 (A), MG132 (B), and lactacystin (C) on the radiation sensitivity of zebrafish embryos. Embryos
were irradiated at 24 hpf and survival was scored every day up to 7 dpf. Results shown represent mean ± SD of triplicate experiments. *, 
statistically significant difference in survival at 6 to 7 dpf.
IκB has previously been shown to cause severe embryonal malformations 
in zebrafish36, 37 and, thus, was not further considered. In addition, 
knockdown of the NF-κBp65 subunit by antisense morpholinos similarly 
caused severe morphologic defects (no tail phenotype) during the first 3 
days of development (Supplementary Fig. S4) consistent with published 
results37 and, thus, was not informative in the context of assaying the 
radiation response. Instead, we used pharmacologic inhibitors that 
disrupt the canonical pathway to NF-κB activation and could be used at 
concentrations that do not interfere with embryonal development. First, 
we tested EP, a ROS scavenger and inhibitor of NF-κBp6538. EP inhibits 
the DNA binding activity of NF-κBp65 by binding to a reactive cysteine 
in the DNA binding site (Cys 38) of NF-κBp6513, which is shared between 
humans and zebrafish (Supplementary Fig. S2C). EP has very recently 
been shown to mitigate deleterious effects of total body irradiation
in mice12. We observed that EP similarly not only protected against 
but also mitigated lethality associated with whole body irradiation of 
zebrafish embryos (Fig. 2A, C, and F). EP was administered at various 
time points ranging from 1 hour prior to radiation exposure to 3 hours 
postirradiation. The ROS scavengers amifostine and DF-1 served as 
positive controls in these experiments as we observed marked protection 
of embryos by these two compounds in earlier work.4, 27 Whereas 
amifostine and DF-1 afforded protection against deleterious effects of 
ionizing radiation when administered prior to or concurrent with 
radiation, neither compound could mitigate the lethal effects of radiation 
when given beyond 15 minutes after ionizing radiation27. In marked 
contrast, EP administered up to 2 hours after radiation significantly 
reduced ionizing radiation–associated lethality (Fig. 2F).
The IKK Inhibitor CDDO-TFEA Mitigates Radiation Effects in 
Zebrafish Embryos
To further address the relevance of NF-κB activation in modulating 
radiation sensitivity of zebrafish embryos we used CDDO-TFEA that 
inhibits NF-κB signaling by interacting with Cys179 of IKKβ, inhibiting 
its activity and preventing phosphorylation and proteasomal degradation 
of IκB39 and, thus, through a molecular mechanism distinct from EP. The 
amino acid sequence around this reactive Cys179 is also highly conserved 
in zebrafish (Supplementary Fig. 2C). CDDO-TFEA protected against 
and mitigated overall lethal effects of radiation in zebrafish embryos 
in a manner similar to EP (Fig. 2B, D , and F). We next determined whether 
mitigation of radiation effects cosegregated with the capacity of the 
compounds under investigation to act as ROS scavengers. This was based 
on the findings that, in addition to directly binding to IKKβ, CDDO has 
been described to induce expression of enzymes catalyzing antioxidant 
reactions in peripheral blood mononuclear cells due to increased nuclear 
accumulation of Nrf2, an oxidant-responsive bZIP transcription factor.40, 41 
Whereas EP is an effective ROS scavenger in irradiated zebrafish embryos, 
CDDO-TFEA did not reduce ROS levels measured 2 hours after radiation 
exposure (Supplementary Fig. S5). Thus, at least the effect of CDDO-TFEA 
on radiation mitigation cannot be ascribed to ROS scavenging, whereas 
in the case of EP, ROS scavenging and NF-κB inhibition may be jointly 
responsible for the beneficial effects of EP in the mitigation setting. Of note, 
the ROS scavengers with no known effect on NF-κB signal transduction 
(amifostine and DF-1) do not mitigate radiation effects if administered 
beyond 15 minutes after ionizing radiation.27 To further probe whether 
IKK inhibition is radioprotective we tested four additional small
molecule IKK inhibitors, i.e. Wedelolactone (IKK inhibitor 2), BMS-
345541 (IKK inhibitor 3) and IKK-2 inhibitors 4 and 5. All four agents 
protected zebrafish embryos against the lethal effects of radiation in a 
manner similar to CDDO-TFEA and EP (Fig. 2E). Moreover, unlike EP 
or CDDO-TFEA, these agents are not known to have antioxidant properties 
and primarily inhibit IκBα phosphorylation by IKKβ (i.e., IKK-2). 
On balance, these results suggest that prolonged and excessive activation of 
the canonical NF-κB pathway is a major contributor to radiation toxicity
in the developing vertebrate organism and that inhibiting this pathway 
may protect the organism against deleterious effects of radiation.
Organ-Specific Radiation Protection by CDDO-TFEA and EP
Having established that EP and CDDO-TFEA provide whole-body pro-
tection against lethal doses of radiation and in consideration of the fact 
that these compounds are in preclinical development, we next determined 
organ-specific radiation protective effects of these two NF-κB inhibitors. 
First, we assessed, by acridine orange staining, organism-wide apoptosis 
in zebrafish embryos determined 6 hours after radiation. Consistent 
with earlier reports 33, we observed increased acridine orange staining 
in the central nervous system and along the body axis of irradiated 
embryos. Both NF-κB inhibitors markedly reduced radiation-induced 
acridine orange staining (Fig. 3). We previously reported that ionizing 
radiation compromised zebrafish kidney function as determined by delayed 
excretion of a fluorescent dextran injected intracardially.27 Treatment with EP 
but not CDDO-TFEA significantly reversed the effect of ionizing radia-
tion on dextran clearance of irradiated embryos to near normal levels, 
suggesting protection against ionizing radiation–induced kidney damage 
(Fig. 4). It is currently unknown whether this effect reflects differences 
in ROS scavenging capacity between the two compounds as described 
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above (Supplementary Fig. S5) or is due to differences in pharmacokinetics 
or pharmacodynamics. In addition, radiation of zebrafish embryos is 
associated with a high incidence of a body axis malformation called “curly-up”
to describe aberrant dorsal curvature of the fish tail. Both CDDO-TFEA 
and EP reduced the incidence of curly-up significantly (Fig. 5).
Finally, we determined the effects of radiation on the developing
gastrointestinal system. This was done in consideration of several prior 
reports suggesting that NF-κB activation protects the gastrointestinal 
tract of higher vertebrates against acute radiation damage.42, 43 Radiation 
protection of the gastrointestinal system was determined in several ways. 
First, we assayed overall gastrointestinal function by scoring “long-term” 
survival of fish irradiated in the presence and absence of EP or CDDO-
TFEA (up to 15 dpf). Fish larvae become dependent on external food 
sources at approximately 6 dpf when the contents of the yolk sac are 
depleted. Significant functional damage to the gastrointestinal system 
will thus lead to death by starvation within 10 days after conception.19 
Conversely, survival of fish beyond two weeks indicates establishment 
of a functionally adequate gastrointestinal system. Both EP and CDDO-
TFEA increased extended survival of zebrafish larvae (Supplementary 
Fig. S6) although this effect was statistically significant only in the case 
of CDDO-TFEA. To address the combined effects of radiation and EP 
or CDDO-TFEA treatment on the developing gastrointestinal system 
further, we determined gastrointestinal lumen formation by use of a 
fluorescent reporter (PED6; ref. 21) that is metabolized and excreted 
through the gastrointestinal system. This analysis revealed severely 
impaired lumen formation of the gastrointestinal system induced by 
ionizing radiation (15 Gy) and partial restoration of lumen formation and 
fluorescent dye excretion by treatment with either EP or CDDO. These 
functional results were complemented by examining the histologic 
appearance of the gastrointestinal system 5 days after radiation exposure 
in the presence and absence of the NF-κB inhibitors under investiga-
tion (Fig. 6). The hindgut mucosal epithelium immediately proximal to 
the cloaca revealed distinct cellular changes associated with sublethal 
ionizing radiation exposure (12 Gy), including irregular shape and 
disorganization of the columnar absorbing cells with redistribution of 
nuclei away from the basal orientation. In addition, decreased goblet cell 
numbers were observed. By contrast, EP and CDDO-TFEA pretreatment 
of irradiated embryos restored, in part, the columnar structure of 
absorbing cells and basal location of nuclei.
Discussion
Our results show that 6 of 6 pharmacologic inhibitors with different 
chemical structures and mode of actions inhibit the canonical pathway 
of NF-κB activation (consisting of IKKβ/IκB/NF-κBp65) and provide 
protection against radiation-induced overall lethality and damage to 
multiple organ systems of the developing zebrafish. By contrast, 3 of 3 
proteasome inhibitors did not afford radiation protection, but radio-
sensitized zebrafish embryos to the lethal effects of ionizing radiation. 
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Figure 2. Protection against and mitigation of lethal effects of radiation by direct NF-κB 
inhibitors. Differential survival of zebrafish embryos  pretreated with EP (A and C) or 
CDDO-TFEA (B and D) and exposed to either 20 or 40 Gy as indicated. E, radiation protection 
of zebrafish embryos exposed to 20 Gy and treated for 1 h prior to irradiation with different 
IKK inhibitors. F, increased survival of irradiated (20 Gy) zebrafish embryos treated with EP 
(1mmol/L) or CDDO-TFEA (1 μmol/L) 2 h post radiation at 24 hpf. Survival was scored at 7 
dpf. All results shown represent mean ± SD of triplicate experiments.*, statistically significant 
differences in survival at 7 dpf between drug-treated and vehicle-treated groups.
BA E
DC
F
8 BODINEJOURNAL 
Taking into account that each of the pharmacologic agents used in this 
study is likely to affect targets other than NF-κB, it is remarkable that 
radioprotection cosegregated with interference with activation of the 
canonical pathway to NF-κB. This observation suggests that NF-κB may 
be the relevant target for radiation protection by pharmacologic IKK/
NF-κB inhibition.
Currently, there is no consensus about the functional contribution of 
NF-κB activation to the radiation response.44 Abundant reports of 
radiosensitization of tumor cells in vitro and in vivo by NF-κB inhibition 
are contrasted by relatively few such reports dealing with normal cells. 
The use of genetically engineered mouse models to monitor NF-κB 
dysfunction in normal tissues has been limited due to embryonal lethality 
observed in IKKβ45 and NF-κBp6546 knockout animals. In cases where 
either conditional knockouts were made or transgenic mice were gener-
ated by forced expression of dominant negative regulators to modulate 
NF-κB activation, the interpretation of results is further complicated by 
compensatory adjustments of homeostasis (for review see ref. 47). The 
present study sidesteps the problems inherent to using genetic models 
by examining the effects of pharmacologic agents used at concentra-
tions that reduce but do not abrogate NF-κB activity. The ease of our 
“assay system,” i.e., observation of overall effects of ionizing radiation 
on zebrafish survival as well as effects on specific target organs, allowed 
us to monitor the effects of drug classes grouped according to target 
specificity and mechanisms of action. This approach had the advantage 
to minimize confounding effects due to unknown, off-target effects 
of any pharmacologic agent. By contrast, and as expected, ablating 
NF-κB activity by targeting IKKβ or NF-κBp65 expression using anti-
sense approaches produced a dramatically different outcome as these 
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Figure 3. Reduction of organism-wide apoptosis by EP and CDDO-TFEA treatment 
preradiation and postradiation. Acridine orange (AO) staining of whole embryos was done 
6 h postradiation at 30 hpf. A, representative examples of control or irradiated fish revealing 
strong AO staining in the central nervous system and along the body axis induced by radiation 
(20 Gy). Regions selected for quantitative evaluation are boxed. B, reduced AO staining in 
CDDO-TFEA- and EP-treated embryos exposed to ionizing radiation. C, PS-341 or MG132 
treatment does not significantly affect AO staining of embryos exposed to ionizing radiation.
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Figure 4. Effects of EP and CDDO-TFEA 
on radiation-induced kidney damage 
as determined by dextran clearance. A, 
Representative images of dextran retention 
in irradiated embryos and effects of EP 
and CDDO-TFEA on this phenomenon. 
B, quantitative representation of dextran 
retention in embryos treated with either 
EP or CDDO-TFEA as indicated; results 
are expressed relative to vehicle-treated, 
nonirradiated controls. *, statistically 
significant differences between the ex- 
perimental groups indicated by brackets.
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interventions were associated with embryonic lethality even in the 
absence of genotoxic stress (see Supplementary Fig. S4 and ref. 46). This 
result is consistent with the view that inhibition of excess NF-κB activity 
after lethal irradiation is beneficial whereas blocking NF-κB expression 
and/or activation altogether, as in genetic knockout/knockdown models, 
is deleterious (even in the absence of radiation). This contention is fur-
ther supported by our finding that EP and CDDO-TFEA at the nontoxic 
concentration used here disrupted TNF-α–induced NF-κB activation but 
not basal NF-κB activity in HeLa cells in vitro (Supplementary Fig. S2). 
Importantly, CDDO-TFEA and EP not only protected against but also 
mitigated the lethal effects of radiation. This result is of interest as it 
points to the importance of sustained NF-κB activation consistent with 
inflammatory responses rather than the burst of NF-κB activity observed 
immediately after radiation exposure. It remains to be seen whether 
other anti-inflammatory agents may be used to mitigate radiation dam-
age to normal tissues in the developing embryo.
Interestingly, radiation protection of zebrafish embryos by NF-κB inhibi-
tors extended to the gastrointestinal system whereas previous work using 
genetically modified mice42 and the TLR5 ligand flagellin43 has implicated 
NF-κB activation in radiation protection of gastrointestinal stem cells. The 
reason(s) for this difference are unclear at this point. However, the TLR5 
ligand flagellin exerts pleiotropic stimulatory effects on multiple signaling 
pathways that include NF-κB but also p38, Erk/mitogen-activated protein 
kinase, and potentially, signal transducers and activators of transcription.48 
It has not been reported which of these multiple effects alone or in combi-
nation is at cause for radioprotection provided by flagellin.43 In addition, 
the NF-κB inhibitory effects of both EP and CDDO-TFEA are completely 
reversible, whereas genetic ablation is not and this circumstance 
could affect outcomes of NF-κB activation in reference to gastrointestinal 
function. Our findings are further consistent with the view that excessive 
NF-κB activation, as observed in the context of chronic inflammation, is 
potentially deleterious to the gastrointestinal system49 and, thus, down-
modulating NF-κB activity but not ablating it altogether can be advanta-
geous in certain settings.50 Although the details of these diverse outcomes 
in different model systems remain to be sorted out, our results clearly 
show that reducing NF-κB activity with a variety of compounds with 
different mechanisms of action diminishes radiation-induced damage to 
several organ systems in the developing zebrafish embryo.
In conclusion, the most salient finding of this study is that direct inhibitors 
of NF-κB activity provided effective protection and mitigation against 
overall lethality and specific organ damage caused by ionizing radiation 
in zebrafish embryos. Direct NF-κB inhibitors also exert antineoplastic 
effects in select model systems as shown extensively for CDDO-TFEA 
and derivatives thereof.51–57 These findings are consistent with a 
favorable therapeutic window for NF-κB inhibitors when used in
combination with radiation and, potentially, chemotherapeutic drugs.
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Figure 5.  EP and CDDO-TFEA 
alleviate radiation-induced malforma-
tions of the body axis. A, representative 
micrographs showing dorsal curvature 
(“curly-up”; cup) in irradiated (20 
Gy) embryos at 72 hpf relative 
to control nonirradiated fish embryos. 
B, quantification of curly-up incidence 
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